We are analyzing https://link.springer.com/article/10.1007/s12672-025-01776-0.

Title:
CAR-T therapy toxicities: the importance of macrophages in their development and possible targets for their management | Discover Oncology
Description:
CAR-T cell therapies have risen to prominence over the last decade, and their indications are increasing with several products approved as early as second line in Large B Cell non-Hodgkin Lymphomas. Their major toxicities are the cytokine release syndrome (CRS) and the Immune-effector Cell Associated Neurotoxicity Syndrome (ICANS). These entities involve a hyperinflammatory cascade which is amplified through the mononuclear phagocytic system (MPS). Herein, we review the immune mediated adverse events related to CAR therapy, including their pathophysiologies, and current therapies. In particular, we discuss the emerging role of the MPS in both the toxicity and efficacy of CAR-T therapy, and possible avenues for the modulation of the MPS to optimize efficacy while minimizing toxicity.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

pubmed, article, google, scholar, cas, mps, cart, therapy, cells, central, cell, car, crs, icans, efficacy, macrophages, patients, cytokine, treatment, blood, toxicity, syndrome, macrophage, depletion, products, antigen, bcell, lymphoma, receptor, liposomal, immune, activation, large, murine, toxicities, inflammatory, tcell, httpsdoiorgs, release, models, cancer, data, system, cytokines, tumor, current, chimeric, refractory, crsicans, study,

Topics {✒️}

lilrb4-targeting antibody-drug conjugates vyxeos [package insert] b-cell tumor lysis bispecific t-cell engagers kte-c19 anti-cd19 car chimeric antigen receptor-modified mitochondrial adp/atp translocase gov/drugsatfda_docs/label/2012/021575s017lbl gov/drugsatfda_docs/label/2007/050718s029lbl gov/drugsatfda_docs/label/2017/209401s000lbl gov/drugsatfda_docs/label/2012/103950s5136lbl managing cytokine-related toxicities autologous harvested t-cells target b-cell signal large b-cell lymphoma t-cell cytotoxicity preference liposome-mediated elimination enhance t-cell activity liposomal doxorubicin + cytosine arabinoside collagen ii-induced arthritis blade-pci trials administered aom/dss mouse model article download pdf macrophage m1/m2 polarization young adult b-cell relapsed/refractory multiple myeloma blood-brain barrier disruption chimeric antigen receptor glucocorticoids transform cd40-triggering related subjects car t-cell therapy explore mps depletion monocyte lineage-derived il-6 article norton current anti-crs regimens acute lymphoblastic leukemia characteristic cytokine profile tnf-α drive fevers van den brandt privacy choices/manage cookies anti-interleukin-6 antibody treatment joseph norton santomasso bd inappropriate t-cell immune-mediated toxicities crs/icans gcs work t-cell cytotoxicity treatment search search b-cell lymphomas full access

Questions {❓}

Increased intensity lymphodepletion and adoptive immunotherapy–how far can we go?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:CAR-T therapy toxicities: the importance of macrophages in their development and possible targets for their management
         description:CAR-T cell therapies have risen to prominence over the last decade, and their indications are increasing with several products approved as early as second line in Large B Cell non-Hodgkin Lymphomas. Their major toxicities are the cytokine release syndrome (CRS) and the Immune-effector Cell Associated Neurotoxicity Syndrome (ICANS). These entities involve a hyperinflammatory cascade which is amplified through the mononuclear phagocytic system (MPS). Herein, we review the immune mediated adverse events related to CAR therapy, including their pathophysiologies, and current therapies. In particular, we discuss the emerging role of the MPS in both the toxicity and efficacy of CAR-T therapy, and possible avenues for the modulation of the MPS to optimize efficacy while minimizing toxicity.
         datePublished:2025-01-15T00:00:00Z
         dateModified:2025-01-15T00:00:00Z
         pageStart:1
         pageEnd:13
         license:http://creativecommons.org/licenses/by/4.0/
         sameAs:https://doi.org/10.1007/s12672-025-01776-0
         keywords:
            Oncology
            Cancer Research
            Surgical Oncology
            Molecular Medicine
            Radiotherapy
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-01776-0/MediaObjects/12672_2025_1776_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-01776-0/MediaObjects/12672_2025_1776_Fig2_HTML.png
         isPartOf:
            name:Discover Oncology
            issn:
               2730-6011
            volumeNumber:16
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Joseph Norton
               url:http://orcid.org/0000-0002-8420-6270
               affiliation:
                     name:University of Minnesota
                     address:
                        name:Internal Medicine Department, Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Patrick Stiff
               affiliation:
                     name:Loyola University Medical Center
                     address:
                        name:Internal Medicine Department, Division of Hematology-Oncology, Loyola University Medical Center, Maywood, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:CAR-T therapy toxicities: the importance of macrophages in their development and possible targets for their management
      description:CAR-T cell therapies have risen to prominence over the last decade, and their indications are increasing with several products approved as early as second line in Large B Cell non-Hodgkin Lymphomas. Their major toxicities are the cytokine release syndrome (CRS) and the Immune-effector Cell Associated Neurotoxicity Syndrome (ICANS). These entities involve a hyperinflammatory cascade which is amplified through the mononuclear phagocytic system (MPS). Herein, we review the immune mediated adverse events related to CAR therapy, including their pathophysiologies, and current therapies. In particular, we discuss the emerging role of the MPS in both the toxicity and efficacy of CAR-T therapy, and possible avenues for the modulation of the MPS to optimize efficacy while minimizing toxicity.
      datePublished:2025-01-15T00:00:00Z
      dateModified:2025-01-15T00:00:00Z
      pageStart:1
      pageEnd:13
      license:http://creativecommons.org/licenses/by/4.0/
      sameAs:https://doi.org/10.1007/s12672-025-01776-0
      keywords:
         Oncology
         Cancer Research
         Surgical Oncology
         Molecular Medicine
         Radiotherapy
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-01776-0/MediaObjects/12672_2025_1776_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs12672-025-01776-0/MediaObjects/12672_2025_1776_Fig2_HTML.png
      isPartOf:
         name:Discover Oncology
         issn:
            2730-6011
         volumeNumber:16
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Joseph Norton
            url:http://orcid.org/0000-0002-8420-6270
            affiliation:
                  name:University of Minnesota
                  address:
                     name:Internal Medicine Department, Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Patrick Stiff
            affiliation:
                  name:Loyola University Medical Center
                  address:
                     name:Internal Medicine Department, Division of Hematology-Oncology, Loyola University Medical Center, Maywood, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Discover Oncology
      issn:
         2730-6011
      volumeNumber:16
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Minnesota
      address:
         name:Internal Medicine Department, Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, USA
         type:PostalAddress
      name:Loyola University Medical Center
      address:
         name:Internal Medicine Department, Division of Hematology-Oncology, Loyola University Medical Center, Maywood, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Joseph Norton
      url:http://orcid.org/0000-0002-8420-6270
      affiliation:
            name:University of Minnesota
            address:
               name:Internal Medicine Department, Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Patrick Stiff
      affiliation:
            name:Loyola University Medical Center
            address:
               name:Internal Medicine Department, Division of Hematology-Oncology, Loyola University Medical Center, Maywood, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Internal Medicine Department, Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, USA
      name:Internal Medicine Department, Division of Hematology-Oncology, Loyola University Medical Center, Maywood, USA

External Links {🔗}(420)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref
Pbgrd

4.98s.

LINK . SPRINGER . COM {}